Skip to main content
SpringerLink
Log in

Clinical Management of Asthma in the 1990s

Current Therapy and New Directions

  • Published:
Drugs Aims and scope Submit manuscript

Summary

Asthma is a serious global health problem affecting nearly 100 million people worldwide. Its rising prevalence and associated morbidity and mortality are of increasing concern. Traditionally, symptomatic control of bronchoconstriction with β2 agonists and theophylline has been the mainstay of therapy. However, during recent years, inflammation has been recognised as the predominant cause of reversible airway obstruction and airway hyperreactivity. As a result, the emphasis in treatment has shifted to the early use of inhaled corticosteroids to control airway inflammation. β2 agonists are best used on an as-needed basis for the relief of acute bronchoconstriction and for the prevention of exercise-induced asthma. Sustained release theophylline or an inhaled long-acting β2 agonist may effectively control nocturnal symptoms. Preliminary studies involving agents active in the 5-lipoxygenase pathway as preventive therapy are encouraging. Further studies are needed to define their role in the management of asthma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gergen PJ, Mullally DI, Evan R III. National survey of prevalence of asthma among children in the United States. 1976 to 1980. Pediatrics 1988; 81: 1–7

    PubMed  CAS  Google Scholar 

  2. Robertson CF, Heycock E, Bishop J, et al. Prevalence of asthma in Melbourne school children: changes over 26 years. BMJ 1991; 302: 1116–68

    Article  PubMed  CAS  Google Scholar 

  3. Burney PGJ, Chinn S, Rona RJ. Has the prevalence of asthma increased in children? Evidence from the national study of health and growth 1973–86. BMJ 1990; 300: 306–10

    Article  Google Scholar 

  4. Haahtela T, Lindholm H, Björksten F, et al. Prevalence of asthma in Finnish young men. BMJ 1990; 301: 266–8

    Article  PubMed  CAS  Google Scholar 

  5. Shaw RA, Crane J, O’Donnell TV, et al. Increasing asthma prevalence in a rural New Zealand adolescent population: 1975–89. Arch Dis Child 1990; 65: 1319–23

    Article  PubMed  CAS  Google Scholar 

  6. Asthma-United States, 1982–1992. Mort Morb Wkly Rep 1995; 43: 952–5

    Google Scholar 

  7. Peat JK, van den Berg RH, Green WF, et al. Changing prevalence of asthma in Australian children. BMJ 1994; 308: 1591–6

    Article  PubMed  CAS  Google Scholar 

  8. Mitchell EA. International trends in hospital admission rates for asthma. Arch Dis Child 1985; 60: 376–8

    Article  PubMed  CAS  Google Scholar 

  9. Storr J, Barrell E, Lenney W. Rising asthma admissions and self referral. Arch Dis Child 1988; 63: 774–9

    Article  PubMed  CAS  Google Scholar 

  10. Gergen PJ, Weiss KB. Changing patterns of asthma hospitalization among children: 1979 to 1987. JAMA 1990; 264: 1688–92

    Article  PubMed  CAS  Google Scholar 

  11. Anderson HR. Increase in hospital admissions for childhood asthma: trends in referral, severity, and readmission from 1970 to 1985 in a health region of the United Kingdom. Thorax 1989; 44: 614–9

    Article  PubMed  CAS  Google Scholar 

  12. Dawson KP, Hickling KG, Mogridge N. Assisted ventilation in severe childhood asthma. NZ Med J 1988; 101: 236–8

    CAS  Google Scholar 

  13. Bosco LA, Knapp DE, Gerstman B, et al. Asthma drug therapy trends in the United States, 1972 to 1985. J Allergy Clin Immunol 1987; 80: 398–402

    Article  PubMed  CAS  Google Scholar 

  14. Jenkins MA, Hurley SF, Bowes G, et al. Use of antiasthma drugs in Australia. Med J Aust 1990; 153: 323–8

    PubMed  CAS  Google Scholar 

  15. Jackson R, Sears MR, Beaglehole R, et al. International trends in asthma mortality: 1970 to 1985. Chest 1988; 94: 914–9

    Article  PubMed  CAS  Google Scholar 

  16. Buist AS. Asthma mortality: what have we learnt? J Allergy Clin Immunol 1989; 84: 275–83

    Article  PubMed  CAS  Google Scholar 

  17. Weiss KB, Wagener DK. Changing patterns of asthma mortality. Identifying target populations at high risk. JAMA 1990; 264: 1683–7

    Article  PubMed  CAS  Google Scholar 

  18. Sears MR, Rea HH, Beaglehole R. Asthma mortality: a review of recent experience in New Zealand. J Allergy Clin Immunol 1987; 80: 319–25

    Article  PubMed  CAS  Google Scholar 

  19. British Thoracic Association. Deaths from asthma in two regions of England. BMJ 1982; 285: 1251–5

    Article  Google Scholar 

  20. Ernst P, Spitzer WO, Suissa S, et al. Risk of fatal and near fatal asthma in relation to inhaled corticosteroid use. JAMA 1992; 268: 3462–4

    Article  PubMed  CAS  Google Scholar 

  21. Buist AS, Vollmer WM. Reflections on the rise in asthma morbidity and mortality. JAMA 1990; 264: 1719–20

    Article  PubMed  CAS  Google Scholar 

  22. Fahy JV, Boushey HA. Controversies involving inhaled β-agonists and inhaled corticosteroids in the treatment of asthma. Clin Chest Med 1995; 16: 715–33

    PubMed  CAS  Google Scholar 

  23. Weiss KB, Gergen PJ, Thomas TA. An economic evaluation of asthma in the United States. N Engl J Med 1992; 326: 862–6

    Article  PubMed  CAS  Google Scholar 

  24. Mellis CM, Peat JK, Bauman AE, et al. The cost of asthma in New South Wales. Med J Aust 1991; 155: 522–8

    PubMed  CAS  Google Scholar 

  25. Marion RJ, Creer TL, Reynolds RVC. Direct and indirect cost associated with the management of childhood asthma. Ann Allergy 1985; 54: 31–4

    PubMed  CAS  Google Scholar 

  26. Mak H, Abbey H, Talamo RC. Prevalence of asthma and health service utilization of asthmatic children in an inner city. J Allergy Clin Immunol 1982; 70: 367–72

    Article  PubMed  CAS  Google Scholar 

  27. Fowler MG, Davenport MG, Garg R. School functioning of US children with asthma. Pediatrics 1992; 90: 939–44

    PubMed  CAS  Google Scholar 

  28. Anderson HR, Bailey PA, Cooper JS, et al. Morbidity and school absence caused by asthma and wheezing illness. Arch Dis Child 1983; 58: 777–84

    Article  PubMed  CAS  Google Scholar 

  29. Goldstein RA, Paul WE, Metcalfe DD, et al. Asthma. Ann Intern Med 1994; 121: 698–708

    PubMed  CAS  Google Scholar 

  30. Djukanovic R, Roche WR, Wilson JW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990; 142: 434–57

    PubMed  CAS  Google Scholar 

  31. Laitinen LA, Heino M, Laitinen A, et al. Damage of the airway epithelium and bronchial reactivity in patients with asthma. Am Rev Respir Dis 1985; 131: 599–606

    PubMed  CAS  Google Scholar 

  32. Laitinen LA, Laitinen A, Haahtela T. Airway mucosal inflammation even in patients with newly diagnosed asthma. Am Rev Respir Dis 1993; 147: 697–704

    PubMed  CAS  Google Scholar 

  33. Beasley R, Roche WR, Roberts JA, et al. Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis 1989; 139: 806–17

    PubMed  CAS  Google Scholar 

  34. Wardlaw AJ, Dunnette S, Gleich GJ, et al. Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Relationship to bronchial hyperactivity. Am Rev Respir Dis 1988; 137: 62–9

    Article  PubMed  CAS  Google Scholar 

  35. Adelroth E, Rosenhall L, Johansson S-A, et al. Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage. The effects of antiasthmatic treatment with budesonide or terbutaline. Am Rev Respir Dis 1990; 142: 91–9

    PubMed  CAS  Google Scholar 

  36. Azzawi M, Bradley B, Jeffery PK, et al. Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am Rev Respir Dis 1990; 142: 1407–13

    PubMed  CAS  Google Scholar 

  37. Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326: 298–304

    Article  PubMed  CAS  Google Scholar 

  38. Jeffery PK, Wardlaw AJ, Nelson FC, et al. Bronchial biopsies in asthma: an ultrastructural, quantitative study and correlation with hyperactivity. Am Rev Respir Dis 1989; 140: 1745–53

    Article  PubMed  CAS  Google Scholar 

  39. Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990; 323: 1033–9

    Article  PubMed  CAS  Google Scholar 

  40. Laitinen LA, Laitinen A, Heino M, et al. Eosinophilic airway inflammation during exacerbation of asthma and its treatment with inhaled steroids. Am Rev Respir Dis 1991; 143: 423–7

    PubMed  CAS  Google Scholar 

  41. Lewis RA, Austen F, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human disease. N Engl J Med 1990; 323: 645–55

    Article  PubMed  CAS  Google Scholar 

  42. Wenzel SE, Westcott JY, Lersen GL. Bronchoalveolar lavage fluid mediator level 5 minutes after allergen challenge in atopic subjects with asthma: relationship to the development of late asthmatic responses. J Allergy Clin Immunol 1991; 87: 540–8

    Article  PubMed  CAS  Google Scholar 

  43. Wenzel SE, Larsen GL, Johnston K, et al. Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid of atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis 1990; 142: 112–9

    PubMed  CAS  Google Scholar 

  44. Drazen JM, O’Brien J, Sparrow D, et al. Recovery of leukotriene E4 from the urine of patients with airway obstruction. Am Rev Respir Dis 1992; 146: 104–8

    PubMed  CAS  Google Scholar 

  45. Joris I, Majno G, Corey EJ, et al. The mechanism of vascular leakage induced by leukotriene E4. Endothelial contraction. Am J Pathol 1987; 126: 19–24

    PubMed  CAS  Google Scholar 

  46. Marom Z, Shelhamer JH, Bach MK, et al. Slow-releasing substances, leukotrienes C4 and D4 increase the release of mucus from the human airways in vitro. Am Rev Respir Dis 1982; 126: 449–51

    PubMed  CAS  Google Scholar 

  47. Kaye MG, Smith LJ. Effects of inhaled leukotriene D4 and platelet activating factor on airway reactivity in normal subjects. Am Rev Respir Dis 1990; 141: 993–7

    PubMed  CAS  Google Scholar 

  48. Arm JP, Spur BW, Lee TH. The effects of inhaled leukotrienes E4 on the airway responsiveness to histamine in subjects with asthma and normal subjects. J Allergy Clin Immunol 1988; 82: 654–60

    Article  PubMed  CAS  Google Scholar 

  49. Martin TR, Pistorese BP, Chi EY, et al. Effects of leukotriene B4 in the human lung. Recruitment of neutrophils into alveolar spaces without a change in pulmonary permeability. J Clin Invest 1989; 84: 1609–19

    Article  PubMed  CAS  Google Scholar 

  50. Nagy L, Lee TH, Goetzl EJ, et al. Complement receptor enhancement and Chemotaxis of human neutrophils and eosinophils by leukotrienes and other lipooxygenase products. Clin Exp Allergy 1983; 71: 394–8

    Google Scholar 

  51. Calhoun WJ, Lavins BJ, Glass M. Effect of Accolate™ (zafirlukast) on bronchoalveolar lavage fluid (BAL) after segmental antigen bronchoprovocation (SBP) in patients with mild to moderate asthma [abstract]. Am J Respir Crit Care Med 1995; 151: A42

    Google Scholar 

  52. Vercelli D, Geha RS. Regulation of IgE synthesis in humans: a tale of two signals. J Allergy Clin Immunol 1991; 88: 285–95

    Article  PubMed  CAS  Google Scholar 

  53. Clutterbuck EJ, Hirst EMA, Sanderson CJ. Human interleukin-5 regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6 and GM-CSF. Blood 1989; 73: 1504–12

    PubMed  CAS  Google Scholar 

  54. Hardy CC, Robinson C, Tattersfield AE, et al. The bronchocon-strictor effect of inhaled prostaglandin D2 in normal and asthmatic men. N Engl J Med 1984; 311: 209–13

    Article  PubMed  CAS  Google Scholar 

  55. Fuller RW, Dixon CMS, Dollery CT, et al. Prostaglandin D2 potentiates airway responsiveness to histamine and methacholine. Am Rev Respir Dis 1986; 133: 252–4

    PubMed  CAS  Google Scholar 

  56. Cuss FM, Dixon CM, Barnes PJ. Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in men. Lancet 1986; 2: 189–92

    Article  PubMed  CAS  Google Scholar 

  57. Barnes PJ, Chung KF, Page CP. Platelet-activating factor as a mediator of allergic disease. J Allergy Clin Immunol 1988; 87: 919–34

    Article  Google Scholar 

  58. Kemp JP. Approach to asthma management. Realities and recommendations. Arch Intern Med 1993; 153: 805–12

    Article  PubMed  CAS  Google Scholar 

  59. Horn CR, Cochrane GM. Management of asthma in general practice. Respir Med 1989; 83: 67–70

    Article  PubMed  CAS  Google Scholar 

  60. Sheffer AL, Bartal M, Bousquet J, et al. Global initiative for asthma: global strategy for asthma management and prevention; NHLBI/WHO workshop report. Bethesda (MD): National Institute of Health, 1995 (Publication No. NIH 95-3659)

    Google Scholar 

  61. International consensus report on diagnosis and treatment of asthma. Eur Respir J 1992; 5: 601–41

    Google Scholar 

  62. Djukanovic R, Wilson JW, Britten KM, et al. Effects of inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992; 145: 669–72

    PubMed  CAS  Google Scholar 

  63. Jeffrey PK, Godfrey RW, Adelroth E, et al. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. Am Rev Respir Dis 1992; 145: 890–9

    Google Scholar 

  64. Juniper EF, Kline PA, Vanzieleghem MA, et al. Effect of long term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonste-roid-dependent asthmatics. Am Rev Respir Dis 1990; 141: 832–6

    Google Scholar 

  65. Vathenen AS, Knox AJ, Wisniewski A, et al. Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma. Am Rev Respir Dis 1991; 143: 1317–21

    PubMed  CAS  Google Scholar 

  66. Kraan J, Koeter GH, Van Der Mark TW, et al. Dosage and time effects of inhaled budesonide on bronchial hyperreactivity. Am Rev Respir Dis 1988; 137: 44–8

    Article  PubMed  CAS  Google Scholar 

  67. Van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, et al. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. Am Rev Respir Dis 1992; 146: 547–54

    PubMed  Google Scholar 

  68. Kerrebijn KF, Van Essen-Zandvliet EEM, Neijens HJ. Effects of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol 1987; 79: 653–9

    Article  PubMed  CAS  Google Scholar 

  69. Salmeron S, Guerin J-C, Godard P, et al. High doses of inhaled corticosteroids in unstable asthma. A multicenter, double blind placebo-controlled study. Am Rev Respir Dis 1989; 140: 167–71

    Article  PubMed  CAS  Google Scholar 

  70. Tarlo SM, Broder I, Davies GM, et al. Six-month double blind, controlled trial of high dose, concentrated beclomethasone dipropionate in the treatment of severe chronic asthma. Chest 1988; 93: 998–1002

    Article  PubMed  CAS  Google Scholar 

  71. Pedersen S, Hansen OR. Budesonide treatment of moderate and severe asthma in children: a dose response study. J Allergy Clin Immunol 1995; 95: 29–33

    Article  PubMed  CAS  Google Scholar 

  72. Smith MJ, Hodson ME. High-dose beclomethasone inhalers in the treatment of asthma. Lancet 1983; 1: 265–8

    Article  PubMed  CAS  Google Scholar 

  73. Hummel S, Lehtonen L, and Study group. Comparison of oralsteroid sparing by high dose and low dose inhaled steroid in the maintenance treatment of severe asthma. Lancet 1992; 340: 1483–7

    Article  PubMed  CAS  Google Scholar 

  74. Haahtela T, Jarvinen M, Kava T, et al. Comparison of a β2 agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325: 388–92

    Article  PubMed  CAS  Google Scholar 

  75. Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a β2 agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992; 90: 32–42

    Article  PubMed  CAS  Google Scholar 

  76. Dompeling E, van Schayck CP, van Grunsven PM, et al. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids. A 4 year prospective study. Ann Intern Med 1993; 118: 770–8

    PubMed  CAS  Google Scholar 

  77. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88: 373–81

    Article  PubMed  CAS  Google Scholar 

  78. Selroos O, Pientinalho A, Lofroos AB, et al. Effects of early vs late intervention with corticosteroids in asthma. Chest 1995; 108: 1228–34

    Article  PubMed  CAS  Google Scholar 

  79. Haahtela T, Jarvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994; 331: 700–5

    Article  PubMed  CAS  Google Scholar 

  80. Waalkens HJ, van Essen-Zandvliet E, Hughes MD, et al. Cessation of long-term treatment with inhaled corticosteroid (budesonide) in children with asthma results in deterioration. Am Rev Respir Dis 1993; 148: 1252–8

    PubMed  CAS  Google Scholar 

  81. Juniper EF, Kline PA, Vanzieleghem MA, et al. Reduction in budesonide after a year of increased use: a randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintained. J Allergy Clin Immunol 1991; 87: 483–9

    Article  PubMed  CAS  Google Scholar 

  82. Brown PH, Blundell G, Greening AP, et al. High dose inhaled steroid therapy and the Cortisol stress response to acute severe asthma. Respir Med 1992; 86: 495–7

    Article  PubMed  CAS  Google Scholar 

  83. Volvovitz B, Amir J, Malik H, et al. Growth and pituitary adrenal function in children with severe asthma treated with inhaled budesonide. N Engl J Med 1993; 329: 1703–8

    Article  Google Scholar 

  84. Ali NJ, Capewell S, Ward MJ. Bone turnover during high dose inhaled corticosteroid treatment. Thorax 1991; 46: 160–4

    Article  PubMed  CAS  Google Scholar 

  85. Ip M, Lam K, Yam L, et al. Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled Steroids. Chest 1994; 105: 1722–7

    Article  PubMed  CAS  Google Scholar 

  86. Kiviranta K, Turpeinen M. Effect of eight months of inhaled beclomethasone dipropionate and budesonide on carbohydrate metabolism in adults with asthma. Thorax 1993; 48: 974–8

    Article  PubMed  CAS  Google Scholar 

  87. Turpeinen M, Sorva R, Juntenen-Backman K. Changes in carbohydrate and lipid metabolism in children with asthma inhaling budesonide. J Allergy Clin Immunol 1991; 88: 384–9

    Article  PubMed  CAS  Google Scholar 

  88. Allen DB, Mullen M, Mullen B. A meta-analysis of the effects of oral and inhaled steroids on growth. J Allergy Clin Immunol 1994; 93: 967–76

    Article  PubMed  CAS  Google Scholar 

  89. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995; 332: 868–75

    Article  PubMed  CAS  Google Scholar 

  90. Nelson HS. β-Adrenergic bronchodilators. N Engl J Med 1995; 333: 499–506

    Article  PubMed  CAS  Google Scholar 

  91. Nelson HS, Raine D Jr, Doner HC, et al. Subsensitivity to the bronchodilator action of albuterol produced by chronic administration. Am Rev Respir Dis 1977; 116: 871–8

    PubMed  CAS  Google Scholar 

  92. Weber RW, Smith JA, Nelson HS. Aerosolized terbutaline in asthmatics: development of subsensitivity with long term administration. J Allergy Clin Immunol 1982; 70: 417–22

    Article  PubMed  CAS  Google Scholar 

  93. Conolly ME, Tashkin DP, Hui KKP, et al. Selective sub-sensitization of β-adrenergic receptors in central airways of asthmatics and normal subjects during long-term therapy with inhaled salbutamol. J Allergy Clin Immunol 1982; 70: 423–31

    Article  PubMed  CAS  Google Scholar 

  94. Hadcock JR, Malbon CC. Down-regulation of β-adrenergic receptors: agonist induced reduction in receptor mRNA levels. Proc Natl Acad Sci USA 1988; 85: 5021–5

    Article  PubMed  CAS  Google Scholar 

  95. Cheung D, Timmers MC, Zwinderman AH, et al. Long-term effects of a long acting β-2 adrenoceptor agonist, salmeterol on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992; 327: 198–203

    Article  Google Scholar 

  96. Cockcroft DW, McPorland CP, Britto SA, et al. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993; 342: 833–7

    Article  PubMed  CAS  Google Scholar 

  97. Taylor DR, Sear MR, Herbison GP, et al. Regular inhaled β-agonists in asthma: effects on exacerbations and lung functions. Thorax 1993; 48: 134–8

    Article  PubMed  CAS  Google Scholar 

  98. Sear MR, Taylor DR, Print CG, et al. Regular inhaled β-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391–6

    Article  Google Scholar 

  99. Chapman KR, Kesten S, Szalai JP. Regular vs as-needed inhaled salbutamol in asthma control. Lancet 1994; 343: 1379–82

    Article  PubMed  CAS  Google Scholar 

  100. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992; 327: 1420–5

    Article  PubMed  CAS  Google Scholar 

  101. D’Alonzo GE, Nathan RA, Henochowicz S, et al. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA 1994; 271: 1412–6

    Article  PubMed  Google Scholar 

  102. Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306: 1034–7

    Article  PubMed  CAS  Google Scholar 

  103. Brambilla C, Chastang C, Georges D, et al. Salmeterol compared with slow release terbutaline in nocturnal asthma: a multicenter, randomized, double blind, double dummy, sequential clinical trial. Allergy 1994; 49: 421–6

    Article  PubMed  CAS  Google Scholar 

  104. Kemp JP, Dockhorn RJ, Busse WJ, et al. Exercise induced bronchospasm. Am J Respir Crit Care Med 1994; 150: 1612–5

    PubMed  CAS  Google Scholar 

  105. Ramage L, Lipworth BJ, Ingram CG, et al. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994; 88: 363–8

    Article  PubMed  CAS  Google Scholar 

  106. Beasley R, Pearce N, Crane J, et al. Asthma mortality and inhaled agonist therapy. Aust NZ J Med 1991; 21: 753–63

    Article  CAS  Google Scholar 

  107. Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981–83: case-control study. Lancet 1989; 1: 917–22

    Article  PubMed  CAS  Google Scholar 

  108. Spitzer WO, Suissa S, Ernst P, et al. The use of β-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326: 501–6

    Article  PubMed  CAS  Google Scholar 

  109. Ernst P, Habbick B, Suissa S, et al. The association between inhaled β-agonist use and life-threatening asthma because of confounding by severity? Am Rev Respir Dis 1993; 148: 75–9

    PubMed  CAS  Google Scholar 

  110. Mullen M, Mullen B, Carey M. The association between β-agonist use and death from asthma. A meta-analytic integration of case-control studies. JAMA 1993; 270: 1842–5

    Article  PubMed  CAS  Google Scholar 

  111. Tattersfield AE. Use of β-2 agonists in asthma: much ado about nothing? Still cause for concern. BMJ 1994; 309: 794–6

    Article  PubMed  CAS  Google Scholar 

  112. Pauwels R. The clinical use of β-receptor agonists; for and against. Life Sci 1993; 52: 2172–9

    Article  Google Scholar 

  113. Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219–24

    Article  PubMed  CAS  Google Scholar 

  114. Shapiro GG, Sharpe M, DeRouen TA, et al. Cromolyn versus triamcinolone acetonide for youngsters with moderate asthma. J Allergy Clin Immunol 1991; 88: 742–8

    Article  PubMed  CAS  Google Scholar 

  115. Bone MF, Kubik MM, Keaney NP, et al. Nedocromil sodium in adults with asthma dependent on inhaled corticosteroids: a double blind, placebo controlled study. Thorax 1989; 44: 654–9

    Article  PubMed  CAS  Google Scholar 

  116. Boulet LP, Cartier A, Cockcroft DW, et al. Tolerance of reduction of oral steroid dosage in severely asthmatic patients receiving nedocromil sodium. Respir Med 1990; 84: 317–23

    Article  PubMed  CAS  Google Scholar 

  117. Woolcock A, Lundback B, Ringdal N. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481–8

    PubMed  CAS  Google Scholar 

  118. Barnes PJ, Greening AP, Neville L, et al. Single-dose slow release aminophylline at night prevents nocturnal asthma. Lancet 1982; 1: 299–301

    Article  PubMed  CAS  Google Scholar 

  119. Nassif EG, Weinberger M, Thompson R, et al. The value of maintenance in steroid-dependent asthma. N Engl J Med 1981; 304: 71–5

    Article  PubMed  CAS  Google Scholar 

  120. Barnes PJ, Adcock IM. Steroid resistance in asthma. Q J Med 1995; 88: 455–68

    CAS  Google Scholar 

  121. Mullarkey M. Immunosuppressive therapy for asthma. Allergy Proc 1995; 16: 81–4

    Article  PubMed  CAS  Google Scholar 

  122. Moss RB. Alternative pharmacotherapies for steroid-dependent asthma. Chest 1995; 107: 817–25

    Article  PubMed  CAS  Google Scholar 

  123. Perera BJC. Efficacy and cost effectiveness of inhaled steroids in asthma in a developing country. Arch Dis Child 1995; 72: 312–6

    Article  PubMed  CAS  Google Scholar 

  124. Goodman DE, Israel E, Rosenberg M, et al. The influence of age, diagnosis, and gender on proper use of metered-dose inhalers. Am J Respir Crit Care Med 1994; 150: 1256–61

    PubMed  CAS  Google Scholar 

  125. Pauwels R. Future of anti-inflammatory therapy in asthma. Allergy 1995; 50 Suppl. 22: 27–31

    Article  PubMed  CAS  Google Scholar 

  126. Drazen J. Clinical studies with agents active on the 5-lipoxygenase pathway. Allergy 1995; 50 Suppl. 22: 22–6

    Article  PubMed  CAS  Google Scholar 

  127. Israel E, Dermarkarian R, Rosenberg M, et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold dry air. N Engl J Med 1990; 323: 1740–4

    Article  PubMed  CAS  Google Scholar 

  128. Israel E, Fischer AR, Rosenberg MA, et al. Pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148: 1447–51

    Article  PubMed  CAS  Google Scholar 

  129. Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild to moderate asthma. Ann Intern Med 1993; 119: 1059–66

    PubMed  CAS  Google Scholar 

  130. Israel E, Cohn J, Dube L, et al. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomised controlled trial. JAMA 1996; 275: 931–6

    Article  PubMed  CAS  Google Scholar 

  131. Cloud ML, Enas GC, Kemp J, et al. A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma. Am Rev Respir Dis 1989; 140: 1336–9

    Article  PubMed  CAS  Google Scholar 

  132. Taylor IK, O’Shaaughnessy KM, Fuller RW, et al. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen induced bronchoconstriction and airway hyperactivity in atopic subjects. Lancet 1991; 337: 690–4

    Article  PubMed  CAS  Google Scholar 

  133. Yamamoto H, Nagata M, Kuramitu K, et al. Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. Am Rev Respir Dis 1994; 150: 254–7

    CAS  Google Scholar 

  134. Lockey RF, Lavins BJ, Snader L. Effects of 13 weeks of treatment with ICI 204,219 (Accolate) in patients with mild to moderate asthma. J Allergy Clin Immunol 1995; 95 Pt 2: (abstract no. 939)

  135. Spector S, Miller CJ, Glass M. 13 week dose response study with Accolate™ (zafirlukast) in patients with mild to moderate asthma [abstract]. Am J Respir Crit Care Med 1995; 151(4) Pt 2: A379

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pulmonary and Critical Care Medicine, Cleveland Clinic Foundation, A-90, 9500 Euclid Avenue, Cleveland, Ohio, 44195, USA

    Prasoon Jain &  Joseph A. Golish

Authors
  1. Prasoon Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph A. Golish
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jain, P., Golish, J.A. Clinical Management of Asthma in the 1990s. Drugs 52 (Suppl 6), 1–11 (1996). https://doi.org/10.2165/00003495-199600526-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199600526-00003

Keywords

Search

Navigation